

Chaitra S Ujjani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8127520/publications.pdf>

Version: 2024-02-01

12
papers

447
citations

1163117

8
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

1137
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterologous <scp>SARSâ€CoV</scp>â€2 vaccinations in patients with Bâ€cell lymphoid malignancies. American Journal of Hematology, 2022, 97, .	4.1	2
2	A multicenter, retrospective study of accelerated venetoclax rampâ€up in patients with relapsed/refractory chronic lymphocytic leukemia. American Journal of Hematology, 2022, 97, .	4.1	3
3	The Impact of Bâ€cell Directed Therapy on SARSâ€CoVâ€2 Vaccine Efficacy in CLL. British Journal of Haematology, 2022, , .	2.5	11
4	Vaccinations in CLL: implications for COVID-19. Blood, 2021, 137, 144-146.	1.4	20
5	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 170-175.	0.4	17
6	Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell, 2021, 39, 1037-1038.	16.8	20
7	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematology,the, 2021, 8, e562-e571.	4.6	28
8	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood, 2020, 136, 1134-1143.	1.4	248
9	Pembrolizumab with Râ€CHOP in previously untreated diffuse large Bâ€cell lymphoma: potential for biomarker driven therapy. British Journal of Haematology, 2020, 189, 1119-1126.	2.5	69
10	Eligibility for CAR Tâ€cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. American Journal of Hematology, 2019, 94, E117-E116.	4.1	19
11	Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 390-395.	0.4	6
12	The acceleration of CARâ€T therapy in nonâ€Hodgkin lymphoma. Hematological Oncology, 2019, 37, 233-239.	1.7	4